Cyclooxygenase 2 Inhibitors
"Cyclooxygenase 2 Inhibitors" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A subclass of cyclooxygenase inhibitors with specificity for CYCLOOXYGENASE-2.
| Descriptor ID |
D052246
|
| MeSH Number(s) |
D27.505.519.389.310.500 D27.505.696.663.850.014.040.500.500.500 D27.505.954.158.030.500.500 D27.505.954.329.030.500.500
|
| Concept/Terms |
Cyclooxygenase 2 Inhibitors- Cyclooxygenase 2 Inhibitors
- Inhibitors, Cyclooxygenase 2
- Cyclooxygenase-2 Inhibitors
- Inhibitors, Cyclooxygenase-2
- Coxibs
- COX-2 Inhibitors
- COX 2 Inhibitors
- Inhibitors, COX-2
- COX2 Inhibitors
- Inhibitors, COX2
|
Below are MeSH descriptors whose meaning is more general than "Cyclooxygenase 2 Inhibitors".
Below are MeSH descriptors whose meaning is more specific than "Cyclooxygenase 2 Inhibitors".
This graph shows the total number of publications written about "Cyclooxygenase 2 Inhibitors" by people in this website by year, and whether "Cyclooxygenase 2 Inhibitors" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2002 | 0 | 1 | 1 |
| 2004 | 0 | 1 | 1 |
| 2005 | 0 | 3 | 3 |
| 2006 | 1 | 1 | 2 |
| 2007 | 1 | 0 | 1 |
| 2008 | 0 | 1 | 1 |
| 2009 | 0 | 1 | 1 |
| 2010 | 3 | 0 | 3 |
| 2013 | 1 | 2 | 3 |
| 2016 | 1 | 0 | 1 |
| 2022 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Cyclooxygenase 2 Inhibitors" by people in Profiles.
-
Kolawole OR, Kashfi K. NSAIDs and Cancer Resolution: New Paradigms beyond Cyclooxygenase. Int J Mol Sci. 2022 Jan 27; 23(3).
-
Janzen C, Sen S, Lei MY, Gagliardi de Assumpcao M, Challis J, Chaudhuri G. The Role of Epithelial to Mesenchymal Transition in Human Amniotic Membrane Rupture. J Clin Endocrinol Metab. 2017 04 01; 102(4):1261-1269.
-
Ramsubhag RR, Massaro CL, Dadich CM, Janeczek AJ, Hoang TT, Mazzio EA, Eyunni S, Soliman KF, Dudley GB. Synthesis of "neoprofen", a rigidified analogue of ibuprofen, exemplifying synthetic methodology for altering the 3-D topology of pharmaceutical substances. Org Biomol Chem. 2016 Aug 16; 14(33):7855-8.
-
Fathali N, Ostrowski RP, Hasegawa Y, Lekic T, Tang J, Zhang JH. Splenic immune cells in experimental neonatal hypoxia-ischemia. Transl Stroke Res. 2013 Apr; 4(2):208-19.
-
Patel AR, Chougule MB, I T, Patlolla R, Wang G, Singh M. Efficacy of aerosolized celecoxib encapsulated nanostructured lipid carrier in non-small cell lung cancer in combination with docetaxel. Pharm Res. 2013 May; 30(5):1435-46.
-
Kashfi K. Dysfunctional cell signaling dynamics in oncology: diagnostic, prognostic and treatment opportunities. Biochem Pharmacol. 2013 Mar 01; 85(5):595-596.
-
White PF, Tang J, Wender RH, Zhao M, Time M, Zaentz A, Yumul R, Sloninsky A, Naruse R, Kariger R, Webb T, Fermelia DE, Tsushima GK. The effects of oral ibuprofen and celecoxib in preventing pain, improving recovery outcomes and patient satisfaction after ambulatory surgery. Anesth Analg. 2011 Feb; 112(2):323-9.
-
Verma S, Kumar M, Nerurkar VR. Cyclooxygenase-2 inhibitor blocks the production of West Nile virus-induced neuroinflammatory markers in astrocytes. J Gen Virol. 2011 Mar; 92(Pt 3):507-15.
-
Zhao Y, Hao Y, Ji H, Fang Y, Guo Y, Sha W, Zhou Y, Pang X, Southerland WM, Califano JA, Gu X. Combination effects of salvianolic acid B with low-dose celecoxib on inhibition of head and neck squamous cell carcinoma growth in vitro and in vivo. Cancer Prev Res (Phila). 2010 Jun; 3(6):787-96.
-
Hao Y, Xie T, Korotcov A, Zhou Y, Pang X, Shan L, Ji H, Sridhar R, Wang P, Califano J, Gu X. Salvianolic acid B inhibits growth of head and neck squamous cell carcinoma in vitro and in vivo via cyclooxygenase-2 and apoptotic pathways. Int J Cancer. 2009 May 01; 124(9):2200-9.